The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia
Leukemic stem cells are multipotent, self-renewing, highly proliferative cells that can withstand drug treatments. Although currently available treatments potentially destroy blast cells, they fail to eradicate leukemic progenitor cells completely. Aldehyde dehydrogenase and STAT3 are frequently up-...
Saved in:
Published in | Haematologica (Roma) Vol. 105; no. 3; pp. 687 - 696 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Italy
Ferrata Storti Foundation
01.03.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Leukemic stem cells are multipotent, self-renewing, highly proliferative cells that can withstand drug treatments. Although currently available treatments potentially destroy blast cells, they fail to eradicate leukemic progenitor cells completely. Aldehyde dehydrogenase and STAT3 are frequently up-regulated in pre-leukemic stem cells as well as in acute myeloid leukemia (AML) expressing the CD34
CD38
phenotype. The Isatin analog, KS99 has shown anticancer activity against multiple myeloma which may, in part, be mediated by inhibition of Bruton's tyrosine kinase activation. Here we demonstrate that KS99 selectively targets leukemic stem cells with high aldehyde dehydrogenase activity and inhibits phosphorylation of STAT3. KS99 targeted cells co-expressing CD34, CD38, CD123, TIM-3, or CD96 immunophenotypes in AML, alone or in combination with the standard therapeutic agent cytarabine. AML with myelodysplastic-related changes was more sensitive than
AML with or without
mutation. KS99 treatment reduced the clonogenicity of primary human AML cells as compared to normal cord blood mononuclear cells. Downregulation of phosphorylated Bruton's tyrosine kinase, STAT3, and aldehyde dehydrogenase was observed, suggesting interaction with KS99 as predicted through docking. KS99 with or without cytarabine showed
preclinical efficacy in human and mouse AML animal models and prolonged survival. KS99 was well tolerated with overall negligible adverse effects. In conclusion, KS99 inhibits aldehyde dehydrogenase and STAT3 activities and causes cell death of leukemic stem cells, but not normal hematopoietic stem and progenitor cells. |
---|---|
AbstractList | Leukemic stem cells are multipotent, self-renewing, highly proliferative cells that can withstand drug treatments. Although currently available treatments potentially destroy blast cells, they fail to eradicate leukemic progenitor cells completely. Aldehyde dehydrogenase and STAT3 are frequently up-regulated in pre-leukemic stem cells as well as in acute myeloid leukemia (AML) expressing the CD34
+
CD38
−
phenotype. The Isatin analog, KS99 has shown anticancer activity against multiple myeloma which may, in part, be mediated by inhibition of Bruton’s tyrosine kinase activation. Here we demonstrate that KS99 selectively targets leukemic stem cells with high aldehyde dehydrogenase activity and inhibits phosphorylation of STAT3. KS99 targeted cells co-expressing CD34, CD38, CD123, TIM-3, or CD96 immunophenotypes in AML, alone or in combination with the standard therapeutic agent cytarabine. AML with myelodysplastic-related changes was more sensitive than
de novo
AML with or without
NPM1
mutation. KS99 treatment reduced the clonogenicity of primary human AML cells as compared to normal cord blood mononuclear cells. Downregulation of phosphorylated Bruton’s tyrosine kinase, STAT3, and aldehyde dehydrogenase was observed, suggesting interaction with KS99 as predicted through docking. KS99 with or without cytarabine showed
in vivo
preclinical efficacy in human and mouse AML animal models and prolonged survival. KS99 was well tolerated with overall negligible adverse effects. In conclusion, KS99 inhibits aldehyde dehydrogenase and STAT3 activities and causes cell death of leukemic stem cells, but not normal hematopoietic stem and progenitor cells. Leukemic stem cells are multipotent, self-renewing, highly proliferative cells that can withstand drug treatments. Although currently available treatments potentially destroy blast cells, they fail to eradicate leukemic progenitor cells completely. Aldehyde dehydrogenase and STAT3 are frequently up-regulated in pre-leukemic stem cells as well as in acute myeloid leukemia (AML) expressing the CD34 CD38 phenotype. The Isatin analog, KS99 has shown anticancer activity against multiple myeloma which may, in part, be mediated by inhibition of Bruton's tyrosine kinase activation. Here we demonstrate that KS99 selectively targets leukemic stem cells with high aldehyde dehydrogenase activity and inhibits phosphorylation of STAT3. KS99 targeted cells co-expressing CD34, CD38, CD123, TIM-3, or CD96 immunophenotypes in AML, alone or in combination with the standard therapeutic agent cytarabine. AML with myelodysplastic-related changes was more sensitive than AML with or without mutation. KS99 treatment reduced the clonogenicity of primary human AML cells as compared to normal cord blood mononuclear cells. Downregulation of phosphorylated Bruton's tyrosine kinase, STAT3, and aldehyde dehydrogenase was observed, suggesting interaction with KS99 as predicted through docking. KS99 with or without cytarabine showed preclinical efficacy in human and mouse AML animal models and prolonged survival. KS99 was well tolerated with overall negligible adverse effects. In conclusion, KS99 inhibits aldehyde dehydrogenase and STAT3 activities and causes cell death of leukemic stem cells, but not normal hematopoietic stem and progenitor cells. Leukemic stem cells are multipotent, self-renewing, highly proliferative cells that can withstand drug treatments. Although currently available treatments potentially destroy blast cells, they fail to eradicate leukemic progenitor cells completely. Aldehyde dehydrogenase and STAT3 are frequently up-regulated in pre-leukemic stem cells as well as in acute myeloid leukemia (AML) expressing the CD34+CD38− phenotype. The Isatin analog, KS99 has shown anticancer activity against multiple myeloma which may, in part, be mediated by inhibition of Bruton’s tyrosine kinase activation. Here we demonstrate that KS99 selectively targets leukemic stem cells with high aldehyde dehydrogenase activity and inhibits phosphorylation of STAT3. KS99 targeted cells co-expressing CD34, CD38, CD123, TIM-3, or CD96 immunophenotypes in AML, alone or in combination with the standard therapeutic agent cytarabine. AML with myelodysplastic-related changes was more sensitive than de novo AML with or without NPM1 mutation. KS99 treatment reduced the clonogenicity of primary human AML cells as compared to normal cord blood mononuclear cells. Downregulation of phosphorylated Bruton’s tyrosine kinase, STAT3, and aldehyde dehydrogenase was observed, suggesting interaction with KS99 as predicted through docking. KS99 with or without cytarabine showed in vivo preclinical efficacy in human and mouse AML animal models and prolonged survival. KS99 was well tolerated with overall negligible adverse effects. In conclusion, KS99 inhibits aldehyde dehydrogenase and STAT3 activities and causes cell death of leukemic stem cells, but not normal hematopoietic stem and progenitor cells. |
Author | Bhattacharya, Priyanjali Tan, Su-Fern Desai, Dhimant Patel, Trupti Iyer, Soumya Claxton, David Annageldiyev, Charyguly Amin, Shantu Loughran, Jr, Thomas P Sharma, Arati Gowda, Krishne Dovat, Sinisa Feith, David J |
AuthorAffiliation | 3 Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, USA 6 Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, USA 7 University of Virginia Cancer Center, Charlottesville, VA, USA 1 Department of Medicine, Division of Hematology and Oncology, Pennsylvania State University College of Medicine, Hershey, PA, USA 4 Department of Integrative Biotechnology, SBST, VIT Vellore, Tamilnadu, India 5 Department of Medicine, Division of Hematology and Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA 2 Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA |
AuthorAffiliation_xml | – name: 4 Department of Integrative Biotechnology, SBST, VIT Vellore, Tamilnadu, India – name: 2 Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA – name: 5 Department of Medicine, Division of Hematology and Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA – name: 6 Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, USA – name: 3 Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, USA – name: 7 University of Virginia Cancer Center, Charlottesville, VA, USA – name: 1 Department of Medicine, Division of Hematology and Oncology, Pennsylvania State University College of Medicine, Hershey, PA, USA |
Author_xml | – sequence: 1 givenname: Charyguly surname: Annageldiyev fullname: Annageldiyev, Charyguly organization: Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA – sequence: 2 givenname: Krishne surname: Gowda fullname: Gowda, Krishne organization: Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, USA – sequence: 3 givenname: Trupti surname: Patel fullname: Patel, Trupti organization: Department of Integrative Biotechnology, SBST, VIT Vellore, Tamilnadu, India – sequence: 4 givenname: Priyanjali surname: Bhattacharya fullname: Bhattacharya, Priyanjali organization: Department of Integrative Biotechnology, SBST, VIT Vellore, Tamilnadu, India – sequence: 5 givenname: Su-Fern surname: Tan fullname: Tan, Su-Fern organization: Department of Medicine, Division of Hematology and Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA – sequence: 6 givenname: Soumya surname: Iyer fullname: Iyer, Soumya organization: Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, USA – sequence: 7 givenname: Dhimant surname: Desai fullname: Desai, Dhimant organization: Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, USA – sequence: 8 givenname: Sinisa surname: Dovat fullname: Dovat, Sinisa organization: Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, USA – sequence: 9 givenname: David J surname: Feith fullname: Feith, David J organization: University of Virginia Cancer Center, Charlottesville, VA, USA – sequence: 10 givenname: Thomas P surname: Loughran, Jr fullname: Loughran, Jr, Thomas P organization: University of Virginia Cancer Center, Charlottesville, VA, USA – sequence: 11 givenname: Shantu surname: Amin fullname: Amin, Shantu organization: Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, USA – sequence: 12 givenname: David surname: Claxton fullname: Claxton, David organization: Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA – sequence: 13 givenname: Arati surname: Sharma fullname: Sharma, Arati email: asharma@pennstatehealth.psu.edu organization: Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31123028$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkdtqGzEQhkVJaRy3b1CCXmAdnXZXugmU0INpwBdNr8VImrU32V0FSQ747bOuk9BcDczM_83Ad0HOpjghIV85W0kp1NUOcIQSh5VgXK8EF1o3H8iC10ZUuhX8jCyYNKxqWKvPyUXO94wJZkz7iZxLzoVkQi_I5m6HdIpPONB1htJPFCYY4pb-_mMMLZC2WDLNBccJc6YjpAdMmR73_L4gHQ84xD7QAfcPOPbwmXzsYMj45aUuyd8f3-9uflW3m5_rm2-3lVetKpWvO2XAcdc4x_X8MujOe9Gp1jupwEHjVS1qJQKAxy6gYVAH3wXg3HQqyCVZn7ghwr19TP382cFG6O2_RkxbC6n0fkBrfK2ABWYaphR33KBiTQjoXANBQzOzrk-sx70bMXicSoLhHfT9ZOp3dhufbMuUka2cAeoE8CnmnLB7y3Jmj7Lsqyx7lGVPsubY5f9330KvduQzk2uXUg |
CitedBy_id | crossref_primary_10_1016_j_blre_2022_100950 crossref_primary_10_1096_fj_202200765R crossref_primary_10_2174_0929867330666230426154055 crossref_primary_10_3390_ijms24119372 crossref_primary_10_2174_0929867330666230408200401 crossref_primary_10_3390_cancers13143523 crossref_primary_10_1002_ardp_202200108 crossref_primary_10_4103_ejh_ejh_24_23 crossref_primary_10_1016_j_jbior_2022_100942 crossref_primary_10_3389_fonc_2020_00393 crossref_primary_10_1016_j_ejmech_2019_111962 crossref_primary_10_2174_1871520622666220610154043 crossref_primary_10_1007_s12015_021_10308_6 crossref_primary_10_3390_cancers13194889 crossref_primary_10_1158_0008_5472_CAN_23_1632 |
ContentType | Journal Article |
Copyright | Copyright© 2020 Ferrata Storti Foundation. Copyright© 2020 Ferrata Storti Foundation 2020 |
Copyright_xml | – notice: Copyright© 2020 Ferrata Storti Foundation. – notice: Copyright© 2020 Ferrata Storti Foundation 2020 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM DOA |
DOI | 10.3324/haematol.2018.212886 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1592-8721 |
EndPage | 696 |
ExternalDocumentID | oai_doaj_org_article_9c54a0d0960441b19e406ddebb6ad8a6 10_3324_haematol_2018_212886 31123028 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: P01 CA171983 |
GroupedDBID | --- 29I 2WC 53G 5GY 5RE 5VS AAFWJ ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW C1A CGR CS3 CUY CVF DIK E3Z EBS ECM EIF EJD F5P FRP GROUPED_DOAJ H13 HYE KQ8 M~E NPM OK1 P2P RHF RHI RNS RPM SJN SV3 TFS TR2 UDS W8F WOQ WOW AAYXX AFPKN CITATION 5PM |
ID | FETCH-LOGICAL-c474t-c5f49ab1b6bb18592a8fcc2f47cb34aba6c452542daacefde90a5dcfda119f4d3 |
IEDL.DBID | RPM |
ISSN | 0390-6078 |
IngestDate | Tue Oct 22 15:11:51 EDT 2024 Tue Sep 17 21:13:09 EDT 2024 Fri Aug 23 02:52:04 EDT 2024 Wed Oct 16 00:43:10 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
License | Copyright© 2020 Ferrata Storti Foundation. https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c474t-c5f49ab1b6bb18592a8fcc2f47cb34aba6c452542daacefde90a5dcfda119f4d3 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049373/ |
PMID | 31123028 |
PageCount | 10 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_9c54a0d0960441b19e406ddebb6ad8a6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7049373 crossref_primary_10_3324_haematol_2018_212886 pubmed_primary_31123028 |
PublicationCentury | 2000 |
PublicationDate | 2020-03-00 20200301 2020-03-01 |
PublicationDateYYYYMMDD | 2020-03-01 |
PublicationDate_xml | – month: 03 year: 2020 text: 2020-03-00 |
PublicationDecade | 2020 |
PublicationPlace | Italy |
PublicationPlace_xml | – name: Italy |
PublicationTitle | Haematologica (Roma) |
PublicationTitleAlternate | Haematologica |
PublicationYear | 2020 |
Publisher | Ferrata Storti Foundation |
Publisher_xml | – name: Ferrata Storti Foundation |
SSID | ssj0020997 |
Score | 2.4260883 |
Snippet | Leukemic stem cells are multipotent, self-renewing, highly proliferative cells that can withstand drug treatments. Although currently available treatments... |
SourceID | doaj pubmedcentral crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 687 |
SubjectTerms | Animals Antigens, CD34 Cytarabine Interleukin-3 Receptor alpha Subunit Isatin Leukemia, Myeloid, Acute - drug therapy Mice Neoplastic Stem Cells |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LTuswELUQC8QG8aZwQV4gdoG6tpN4yUUgHgIWgMQu8mMiKtoUlfZK_P2dsVPUrtiwjZ3YmnE8Z-zjY8aO81qUDiN1pp30mKAEyJwTkHlnu0EL8BDZhPcP-fWLun3Vr3NXfREnLMkDJ8OdGa8VvkZIGyO3EwYwBOE_6VxuQ2mT2LbQs2SqTbXoPGjcPzCYHGEUTIfmJKKHszdLYqgj2nYQ5SnO3CWdo54LSlG7fy4gLZIl56LP1Tpba2EjP0_d3WBL0GyyrfMGmxh-8RMeiZxxhXyTrdy3--Vb7BFHAW9G_2DAb4i203Db0GoNv3syhicW-CcnLWea8fiQuDrjT071_HQCfPgFg1E_8AFM32HYt9vs5ery-eI6a69QyLwq1CTzulbGOuFy9ECpTc-Wtfe9WhXeSWWdzT1tbKpesNZDHcB0rQ6-DlYIU6sgd9hyM2pgj3Es9YUyOcnZKGERGUgER1JDyGubQ7fDspkNq4-klFFhhkE2r2Y2r8jmVbJ5h_0lQ3_XJZ3r-AC9X7Xer37yfoftJu98f0YigJQImjqsWPDbQjuLJU3_LepqF5gtyULu_0bHDthqjzLzyFb7w5Yn4ykcInyZuKM4Uv8Dto_vbQ priority: 102 providerName: Directory of Open Access Journals |
Title | The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31123028 https://pubmed.ncbi.nlm.nih.gov/PMC7049373 https://doaj.org/article/9c54a0d0960441b19e406ddebb6ad8a6 |
Volume | 105 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELXaHhAXBC0fC23lA-KW3fXaTuJjW1EV0AISVOot8seErtg41XYXqf-eGSepdq-9xokdzYw879nPY8Y-5rUoHWbqTDvpkaAEyJwTkHlnp0EL8JDUhPPv-dW1-nqjb_aYHs7CJNG-d4txXDbjuLhN2sq7xk8Gndjk5_yiQFgrCznZZ_uFlANF71kWHQVNWwcGeREmwO68nETgMLm1VAe1pR0HUY5x0i5LusJIIuaQU7qPfSs1pQr-W2lpVzK5lYMuX7IXPXjkZ91PvmJ7EA_Z0VnE0ZoH_oknOWdaJz9kz-b9rvkR-4GxwGP7D5b8C4l3IreR1mz4t1_G8E4Lfs-pojPNe7whxc7qntN7frMG3jzAsl0EvoTNX2gW9jW7vvz8--Iq6y9SyLwq1DrzulbGOuFy9EOpzcyWtfezWhXeSWWdzT1tb6pZsNZDHcBMrQ6-DlYIU6sg37CD2EZ4xzi2-kKZnIraKGERH0iESFJDyGubw3TEssGG1V1XL6NCnkHmrwbzV2T-qjP_iJ2ToR_fpWrX6UG7-lP1Pq-M1wpDh9gWojcnDCAMwXnZudyG0mInbzvvPHYzuHTEih2_7Yyz24LBlqpr98H1_slffmDPZ0TKk1DtmB2sVxs4QeSydqeJ8Z-meP0PZcDwaw |
link.rule.ids | 230,315,733,786,790,870,891,2115,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEXHi2F5ekD4pbsJraT-Fgqqi3tFiRa1FvkV-iqG6faZpHKr2fsJNUuN7jGiRPnsz3feD6PAT5kVVIotNQRV1Sjg2JspFRiI63kxPDEahvUhLPTbHrOvlzwiy3gw16YINrXah67RR27-WXQVl7XejzoxMbfZgc50lqa0_E9uI_jNeWDk977WX4zaAgeCPSM0AR2O-YoUofxpfSZUBsfc0iKGKftovCHGFFkHXTiT2RfM04hh_-aYdoUTa5ZocMn8GP4_k58chWvWhXr33-ldvznBj6Fxz0vJftd8TPYsm4HdvcdNqO-JR9JUIqGJfgdeDDrA_K78BW7GXHNL7sgR14X5Ih0fjmIHH8XgnQy8xvik0X7KZXUXgy0vCH-Pr1qLalv7aKZG7Kwqytbz-VzOD_8fHYwjfozGiLNctZGmldMSJWoDCEuuEhlUWmdVizXijKpZKZ95JSlRkptK2PFRHKjKyOTRFTM0D3Ydo2zL4Fgqc6ZyHy-HJZIpB4U2Rfl1mSVzOxkBNEATnndpeIo0YXxuJYDrqXHtexwHcEnj-DdvT6RdrjQLH-W_d8uheYMe6V35JAYqkRYZDg45SuVSVNIrORFB_tdNUNfGUG-0SE23rNZgjCHxN09rK_--8n38HB6NjspT45Oj1_Do9T7_kEP9wa22-XKvkWC1Kp3YTj8AbeREXw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUXHi2PpRR8QNySrGPn4WMpXbWULZWgUsUl8it01U2y2maRyq_vjJNUuxx7jR1Hzmd7vvF8HhPyKS1ZrsFSB4nmBhwU6wKtmQuMVmObMGecVxNOz9LjC_HtMrlcu-rLi_aNnoX1vArr2ZXXVi4qEw06seh8epgBreUZjxa2jB6TJzBn42xw1HtfCw-E-gCCBO8IzGB3ao4DfYiuFGZDbTDuwPIQlu48x4uMODAPPsZb2dcMlM_jv2acNoWTa5Zo8pz8HvrQCVCuw1WrQ_Pvv_SOD-rkC_Ks56f0oKvykjxy9Q7ZPaihK9Ut_Uy9YtRvxe-Q7WkfmN8lP2C40br56-b0BPVBNVU1bgvR059S0k5ufkMxaTQurbRCUdDyhmI9s2odrW7dvJlZOnera1fN1CtyMTn6dXgc9Hc1BEZkog1MUgqpNNMpQJ0nMlZ5aUxcisxoLpRWqcEIqoitUsaV1smxSqwprWJMlsLy12Srbmr3llAoNZmQKebNEUwBBeHAwnjibFqq1I1HJBgAKhZdSo4CXBnEthiwLRDbosN2RL4givd1MaG2f9As_xT9Hy-kSQSMTnTogCBqJh0wHVj6tU6VzRU08qaD_r6ZYbyMSLYxKDa-s1kCUPsE3j207x785keyff51Unw_OTvdI09j3ALwsrj3ZKtdrtw-8KRWf_Az4g4_9hP8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+novel+Isatin+analog+KS99+targets+stemness+markers+in+acute+myeloid+leukemia&rft.jtitle=Haematologica+%28Roma%29&rft.au=Annageldiyev%2C+Charyguly&rft.au=Gowda%2C+Krishne&rft.au=Patel%2C+Trupti&rft.au=Bhattacharya%2C+Priyanjali&rft.date=2020-03-01&rft.issn=0390-6078&rft.eissn=1592-8721&rft.volume=105&rft.issue=3&rft.spage=687&rft.epage=696&rft_id=info:doi/10.3324%2Fhaematol.2018.212886&rft.externalDBID=n%2Fa&rft.externalDocID=10_3324_haematol_2018_212886 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0390-6078&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0390-6078&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0390-6078&client=summon |